Captopril is an orally active inhibitor of angiotensin-converting enzyme (ACE) and has been
widely studied in the treatment of patients with mild to moderate essential hypertension …

The renin-angiotensin system is an important regulator of vascular resistance in many
patients with hypertension and congestive heart failure. To quantitatively evaluate this …

The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors
may be mediated by the endogenous opioid system. The opioid antagonist naloxone has …

Acute exercise increases vascular endothelial growth factor (VEGF), transforming growth
factor-β1 (TGF-β1), and basic fibroblast growth factor (bFGF) mRNA levels in skeletal …

The pharmacodynamic effects and acceptability of perindopril (4 mg daily) and
hydrochlorothiazide (25 mg daily) given alone or in combination for 1 month were …

Angiotensin converting enzyme inhibitors reduce blood pressure without reflex tachycardia,
possibly as a result of enhanced hypothesis that this results from the removal of the …

The inter-relationship between the pharmacokinetic and pharmacodynamic behaviour of
ACE inhibitors is reviewed. First, some of the methods which have been used to assess the …

Indocyanine green estimated apparent liver blood flow was measured in normal volunteers
following glyceryl trinitrate, propranolol, isosorbide mononitrate and captopril. Glyceryl …

Captopril is an angiotensin-converting enzyme inhibitor (ACEI) used in the treatment of
hypertension and congestive heart failure and has demonstrated its cardiovascular effects in …

The fall in blood pressure produced by captopril is not accompanied by a compensatory
tachycardia. Angiotensin converting enzyme may participate in the metabolism of …